What are the listed companies of PD 1?

PD- 1 is an important immunosuppressive molecule, which has been used in the field of anticancer. 20 18, 18 February, the first PD- 1 antibody drug cindilizumab injection for Hodgkin's lymphoma in China was approved for marketing. At present, more and more patients begin to use domestic PD- 1 drugs for tumor treatment. As an investor, you should know about relevant listed companies, so what are the listed companies of PD 1?

What are the listed companies of PD 1?

The listed companies that produce PD- 1 drugs mainly include Cinda Bio, Baekje Shenzhou, Hengrui Pharma and Junshi Bio. Only Hengrui Pharma is listed on the A-share market, and the other three companies can make purchases through Hong Kong stock accounts.

1 Cinda Bio (HK 180 1): The company's main products are PD- 1 antibody Cinda monoclonal antibody (IBI-308), bevacizumab (Avastin) biological drug IBI-305 and rituximab (/rituximab).

2 Baekje Shenzhou (HK6 160): Baekje Shenzhou Co., Ltd. was established on 201010, which is a company mainly engaged in biopharmaceutical business. The company is mainly engaged in the research, development, production and sales of innovative molecular targeting and immune tumor drugs for cancer treatment.

Hengrui Pharma (600276): The company is one of the largest R&D and production bases of anti-tumor drugs, surgical drugs and contrast agents in China. The company's products cover many fields, such as anti-tumor drugs, surgical anesthesia drugs, special infusion, contrast agents, cardiovascular drugs and so on.

4 Junshi Bio (HK1877): 201817, Yi Tuo (generic name "Tripril Monoclonal Antibody", project code "JS00 1") was approved for listing by NMPA and became domestic.